Skip to main content
. 2023 Mar 14;100(11):e1109–e1122. doi: 10.1212/WNL.0000000000206750

Figure 2. Evolution of Neurologic Disability in Patients With SPMS Treated With AHSCT and Matched Patients Treated With Other Anti-inflammatory DMTs.

Figure 2

Annualized EDSS Change Together With 95% CIs 1–10 years after Treatment Start for (A) Propensity Score–Matched Treatment Groups and (B) the Overlap Weighting–Matched Groups. Abbreviations: AHSCT = autologous hematopoietic stem cell transplantation; DMTs = disease-modifying therapies (Beta Interferons, azathioprine, Glatiramer Acetate, Mitoxantrone, Fingolimod, Natalizumab, Methotrexate, Teriflunomide, Cyclophosphamide, Dimethyl Fumarate, and Alemtuzumab); EDSS = Expanded Disability Status Scale; SPMS = secondary progressive multiple sclerosis.